Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

2(40.0%)

N/A

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 4(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06792851Not ApplicableCompleted

ECHO-012 Kosmos Bladder Clinical Validation Study

Role: collaborator

NCT05132907Phase 1Completed

Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

Role: collaborator

NCT05833100Not ApplicableTerminated

Method Comparison/User Evaluation of the i-SENS Self-Monitoring Blood Glucose / β-Ketone System

Role: collaborator

NCT03143816Phase 4Completed

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

Role: collaborator

NCT02789319Phase 4Completed

DTS Blood Glucose Monitor System Surveillance Program SubStudy 1

Role: collaborator

All 5 trials loaded